This content requires an NEJM.org account. Create a free account now. Already have an account? Sign in .

Quick Take Free Preview

Fazirsiran for Alpha1-Antitrypsin Deficiency

Continue to access content

Select an option below:

This content requires an account.

Create Account

Already have an account?

Sign In

Liver disease associated with mutant alpha1-antitrypsin results from accumulation of mutant Z-AAT in hepatocytes. Can fazirsiran, an RNA interference therapeutic, reduce liver Z-AAT levels? New research findings are summarized in a short video.

This content requires an NEJM.org account.

Create Account